Roche’s Q3 19 sales growth of 13% CER is the highest quarterly growth in the last eight years. In oncology, the newer drugs have clearly taken over the growth baton from the older ones, further supported by multiple sclerosis, haemophilia and immunology drugs. Despite the looming biosimilar risk, a third consecutive guidance upgrade this year is a reflection of the group’s sustained innovation and efficient lifecycle management.
18 Oct 2019
Strongest quarter in eight years
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strongest quarter in eight years
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
18 Oct 2019 -
Author:
Surbhit Gupta -
Pages:
5
Roche’s Q3 19 sales growth of 13% CER is the highest quarterly growth in the last eight years. In oncology, the newer drugs have clearly taken over the growth baton from the older ones, further supported by multiple sclerosis, haemophilia and immunology drugs. Despite the looming biosimilar risk, a third consecutive guidance upgrade this year is a reflection of the group’s sustained innovation and efficient lifecycle management.